Alkem Laboratories Ltd, a leading pharmaceutical company, announced today the launch of its new product- Perampil (Perampanel) tablet in three strengths i.e. 2 mg, 4 mg and 6 mg.
This new drug- Perampil is a broad spectrum anti-epileptic drug (AED), which works by acting as a non-competitive AMPA receptor antagonist. The tablets will be available at affordable prices in order to make the treatment accessible to patients & healthcare providers and thereby, improve their quality of life.
The formulation of these tablets has been approved by Drugs Controller General of India (DCGI) to be used as adjunctive therapy in treating partial-onset seizures in epilepsy patients, who are aged 4 years and above. In addition to this, it can also be used as adjunctive therapy in treating primary generalised tonic-clonic seizures (also known as grand mal seizures) in epilepsy patients aged 12 years and above.
This launch reaffirms the company’s commitment towards enhancing epilepsy care by bringing a range of affordable, quality products to make the treatment more accessible to patients and health care professionals.
At the time of market closing on Thursday, the company's stock was trading at Rs 3,129.70, up by 1.03 per cent on BSE.